NEW DELHI: In October 2024, India’s pharmaceutical market continued to show robust performance, with leading companies like Cipla, Lupin, Sun Pharmaceutical, Alkem Laboratories, and Delius Pharma driving much of the growth. These firms benefitted from a mix of new product launches, price increases, and a strong demand in key therapeutic segments such as cardiology, dermatology, and diabetes care. This growth further solidified India’s position as a global leader in the generics sector.
Cipla, Lupin, and Sun Pharmaceutical posted strong revenue figures, continuing their dominant presence in the market. Alkem Laboratories also contributed to the overall market growth, helping propel the Indian pharmaceutical industry, which expanded by 6.1% year-on-year in October 2024. This growth was largely driven by price increases and new product innovations, which offset weaker volume growth in some segments.
The generics sector in India remains a significant player on the global stage, as the country is a top exporter of affordable medications, particularly for chronic conditions. As demand continues to rise both domestically and internationally, companies like Cipla, Lupin, Sun Pharmaceutical, Alkem, and Delius Pharma are well-positioned for continued success. The pharmaceutical industry is expected to maintain its growth momentum, with these companies contributing significantly to the broader sector’s success in the coming months.
